Table 2. Adverse events and treatment-related adverse events occurring in ≥ 2.5% of patients (N = 41).

Adverse event †	n	(%)
Any AE ‡	21	(51.2)
Any SAE	0	(0)
AEs leading to discontinuation	0	(0)
AEs occurring in ≥ 2 patients
Nausea	6	(14.6)
Dizziness / vertigo	3	(7.3)
Anemia	2	(4.9)
Abdominal pain	2	(4.9)
Emesis	2	(4.9)
Epigastric pressure pain	2	(4.9)
Flu like symptoms	2	(4.9)
FSS increased ≥ 1	2	(4.9)
Total bilirubin increase	2	(4.9)
Any treatment-related AE	13	(31.7)
Treatment-related AEs occurring in ≥ 2 patients
Nausea	4	(9.8)
Total bilirubin increase	2	(4.9)
Anemia	2	(4.9)
FSS increased ≥ 1	2	(4.9)

AE = adverse event; FSS = fatigue severity scale: SAE = serious adverse event.

^† Fatigue is not included as it was part of the inclusion criteria. An increase of ≥ 1 point in the FSS was documented as an AE.

^‡ Any AE occurred in 21 out of 41 patients (51.2%).